PDS Biotechnology Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 16, 2026, reporting financial results and balance sheet data for the three and nine months ended on that date.
Key Highlights
- Net loss of $7,620,925 for the three months ended September 30, 2026, compared to a net loss of $9,009,411 in the same period of 2025, according to the filing.
- Cash and cash equivalents of $15,245,081 as of September 30, 2026, down from $26,711,969 at December 31, 2025, the company disclosed.
- Total debt eliminated: both the current portion of debt ($5,130,372) and long-term debt ($11,733,350) carried at December 31, 2025 were reduced to zero by September 30, 2026, per the balance sheet.
- Shares outstanding nearly doubled: common shares issued and outstanding rose to 104,213,429 at September 30, 2026 from 54,878,233 at December 31, 2025, the filing states.
- At-the-market equity proceeds of $12,548,941 were raised in the third quarter of 2026 alone, based on the statements of changes in stockholders' equity.
- Accumulated deficit reached $241,327,060 as of September 30, 2026, the registrant reported.
PDS Biotechnology's Third-Quarter 2026 Financial Results and Capital Activity
According to the filing, PDS Biotechnology Corporation (NASDAQ:PDSB), a Delaware-incorporated clinical-stage biotechnology company headquartered in Princeton, New Jersey, reported a net loss of $7,620,925 for the three months ended September 30, 2026. This compares to a net loss of $9,009,411 for the same quarter of 2025. For the nine months ended September 30, 2026, the company disclosed a net loss of $24,720,556, versus $26,932,586 in the nine months ended September 30, 2025.
The filing shows total operating expenses of $5,896,104 for the third quarter of 2026, comprised of research and development expenses of $2,051,213 and general and administrative expenses of $3,844,891. Research and development expenses declined from $4,576,389 in the third quarter of 2025, the registrant reported. Net loss per share, basic and diluted, was $(0.11) for the three months ended September 30, 2026, compared to $(0.19) in the prior-year period, based on weighted average shares outstanding of 71,936,955 and 46,869,531, respectively.
The company disclosed significant equity capital activity during the quarter. Net proceeds from the at-the-market program totaled $12,548,941 in Q3 2026, and an additional $2,507,932 was raised through other common stock issuances. The registrant also recorded an issuance of pre-funded warrants valued at $3,568,052 and an issuance of a contingent milestone commitment valued at $3,462,488. Total stockholders' equity was $13,495,140 at September 30, 2026, recovering from a deficit position of $(3,579,739) at June 30, 2026, according to the filing. The authorized share count was increased to 300,000,000 from 150,000,000 during the period, the filing noted.
What Was Disclosed
PDS Biotechnology filed its quarterly report covering the period ended September 30, 2026, disclosing a net loss of $7,620,925, cash of $15,245,081, the full repayment of outstanding debt, and a near-doubling of shares outstanding driven by substantial at-the-market and other equity issuances during the quarter.




Please wait processing your request...